About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA
Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics
10 June 2020
Nanobiotix announces revenue for second quarter 2020 and first half year 2020
17 July 2020
Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA
Published by
Julie Ficheux
on
17 June 2020
